L
Lingyi Huang
Researcher at Merck & Co.
Publications - 40
Citations - 4250
Lingyi Huang is an academic researcher from Merck & Co.. The author has contributed to research in topics: Chemistry & Virus. The author has an hindex of 23, co-authored 28 publications receiving 4133 citations. Previous affiliations of Lingyi Huang include United States Military Academy & Drexel University.
Papers
More filters
Journal ArticleDOI
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
John W. Shiver,Tong-Ming Fu,Ling Chen,Danilo R. Casimiro,Mary-Ellen Davies,Robert K. Evans,Zhiqiang Zhang,Adam J. Simon,Wendy L. Trigona,Sheri Dubey,Lingyi Huang,Virginia Harris,Romnie Long,Xiaoping Liang,Larry Handt,William A. Schleif,Lan Zhu,Daniel C. Freed,Natasha Persaud,Liming Guan,Kara Punt,Aimin Tang,Minchun Chen,Keith A. Wilson,Kelly B. Collins,Gwendolyn J. Heidecker,V. Rose Fernandez,Helen C. Perry,Joseph G. Joyce,Karen M. Grimm,James C. Cook,Paul M. Keller,Denise S. Kresock,Henryk Mach,Robert D. Troutman,Lynne Isopi,Donna M. Williams,Zheng Xu,Kathryn E. Bohannon,David B. Volkin,David C. Montefiori,Ayako Miura,Georgia R. Krivulka,Michelle A. Lifton,Marcelo J. Kuroda,Jörn E. Schmitz,Norman L. Letvin,Michael J. Caulfield,Andrew J. Bett,Rima Youil,David C. Kaslow,Emilio A. Emini +51 more
TL;DR: The replication-defective adenovirus is a promising vaccine vector for development of an HIV-1 vaccine and elicited by a replication-incompetent Ad5 vector, used either alone or as a booster inoculation after priming with a DNA vector.
Journal ArticleDOI
Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene
Danilo R. Casimiro,Ling Chen,Tong-Ming Fu,Robert K. Evans,Michael J. Caulfield,Mary-Ellen Davies,Aimin Tang,Minchun Chen,Lingyi Huang,Virginia Harris,Daniel C. Freed,Keith A. Wilson,Sheri Dubey,De-Min Zhu,Denise K. Nawrocki,Henryk Mach,Robert D. Troutman,Lynne Isopi,Donna M. Williams,William M. Hurni,Zheng Xu,Jeffrey G. Smith,Su Wang,Xu Liu,Liming Guan,Romnie Long,Wendy L. Trigona,Gwendolyn J. Heidecker,Helen C. Perry,Natasha Persaud,Timothy J. Toner,Qin Su,Xiaoping Liang,Rima Youil,Michael Chastain,Andrew J. Bett,David B. Volkin,Emilio A. Emini,John W. Shiver +38 more
TL;DR: Results are suggestive of an immunization strategy for humans that is centered on use of the adenovirus vector and in which existing adenavirus immunity may be overcome by combined immunization with adjuvanted DNA and adenvirus vector boosting.
Journal ArticleDOI
Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas
TL;DR: The role played by the AKT2 kinase in the signaling pathways of various mitogenic growth factors implicated in the development of pancreatic cancer suggests that alteration ofAKT2 may be an important component in the pathogenesis of a substantial subset of PDACs.
Journal ArticleDOI
Attenuation of Simian Immunodeficiency Virus SIVmac239 Infection by Prophylactic Immunization with DNA and Recombinant Adenoviral Vaccine Vectors Expressing Gag
Danilo R. Casimiro,Fubao Wang,William A. Schleif,Xiaoping Liang,Zhiqiang Zhang,Timothy W. Tobery,Mary-Ellen Davies,Adrian B. McDermott,David H. O’Connor,Arthur Fridman,Ansu Bagchi,Lynda G. Tussey,Andrew J. Bett,Adam C. Finnefrock,Tong-Ming Fu,Aimin Tang,Keith A. Wilson,Minchun Chen,Helen C. Perry,Gwendolyn J. Heidecker,Daniel C. Freed,Anthony Carella,Kara Punt,Kara J. Sykes,Lingyi Huang,Virginia I. Ausensi,Margaret Bachinsky,Usha Sadasivan-Nair,David I. Watkins,Emilio A. Emini,John W. Shiver +30 more
TL;DR: The prophylactic efficacy of DNA and replication-incompetent adenovirus serotype 5 (Ad5) vaccine vectors expressing simian immunodeficiency virus (SIV) Gag was examined in rhesus macaques using an SIVmac239 challenge, and virus control was short-lived.
Journal ArticleDOI
Vaccine-Induced Cellular Immune Responses Reduce Plasma Viral Concentrations after Repeated Low-Dose Challenge with Pathogenic Simian Immunodeficiency Virus SIVmac239
Nancy A. Wilson,Jason S. Reed,Gnankang Napoé,Shari M. Piaskowski,Andy Szymanski,Jessica Furlott,Edna J. Gonzalez,Levi Yant,Nicholas J. Maness,Gemma E. May,Taeko Soma,Matthew R. Reynolds,Eva G. Rakasz,Richard Rudersdorf,Adrian B. McDermott,Adrian B. McDermott,David H. O’Connor,Thomas C. Friedrich,David B. Allison,Amit Patki,Louis J. Picker,Dennis R. Burton,Jing Lin,Lingyi Huang,Deepa Patel,Gwendolyn Heindecker,Jiang Fan,Michael P. Citron,Melanie Horton,Fubao Wang,Xiaoping Liang,John W. Shiver,Danilo R. Casimiro,David I. Watkins +33 more
TL;DR: Investigation of whether vaccine-induced cellular immunity in the absence of any Env-specific antibodies can control viral replication following multiple low-dose challenges with the highly pathogenic SIVmac239 isolate results give hope that a vaccine designed to induce cellular immune responses might control viral replicate.